April 29, 2020 – Like all Paragon Biosciences companies, Harmony has understood the importance of establishing a great workplace culture right from their start, with patients at the heart of all they do. In 2017, we at Paragon founded Harmony Biosciences using our proprietary Paragon Innovation Capital™ approach to accelerate development of life science breakthroughs. We identified a debilitating unmet need in neurology disorders of wakefulness, isolated a possible scientific solution and then created a company around it. Harmony was able to earn FDA approval and launch its first product in 2019.

Harmony is achieving its mission and ours, each and every day.

Learn more about the recognition here. Additional details are included in the Harmony press release.

QuantX Artificial Intelligence Breast Cancer Diagnosis System Receives 2020 Gold Edison Award
Philadelphia Magazine features a Paragon portfolio company as a leader in cell and gene therapy innovation